Back

A human papillomavirus 16 E2-TopBP1 dependent SIRT1-p300 acetylation switch regulates mitotic viral and human protein levels

Tadimari Prabhakar, A.; James, C. D.; Youssef, A. H.; Hossein, R. A.; Hill, R. D.; Bristol, M. L.; Dubey, A.; Wang, X.; Morgan, I. M.

2024-01-16 molecular biology
10.1101/2024.01.15.575713 bioRxiv
Show abstract

An interaction between human papillomavirus 16 (HPV16) E2 and the cellular proteins TopBP1 and BRD4 is required for E2 plasmid segregation function. The E2-TopBP1 interaction promotes increased mitotic E2 protein levels in U2OS and N/Tert-1 cells, as well as in human foreskin keratinocytes immortalized by HPV16 (HFK+HPV16). SIRT1 deacetylation reduces E2 protein stability and here we demonstrate that increased E2 acetylation occurs during mitosis in a TopBP1 interacting dependent manner, promoting E2 mitotic stabilization. p300 mediates E2 acetylation and acetylation is increased due to E2 switching off SIRT1 function during mitosis in a TopBP1 interacting dependent manner, confirmed by increased p53 stability and acetylation on lysine 382, a known target for SIRT1 deacetylation. SIRT1 can complex with E2 in growing cells but is unable to do so during mitosis due to the E2-TopBP1 interaction; SIRT1 is also unable to complex with p53 in mitotic E2 wild type cells but can complex with p53 outside of mitosis. E2 lysines 111 and 112 are highly conserved residues across all E2 proteins and we demonstrate that K111 hyper-acetylation occurs during mitosis, promoting E2 interaction with Topoisomerase 1 (Top1). We also demonstrate that K112 ubiquitination promotes E2 proteasomal degradation during mitosis. The results present a model in which the E2-TopBP1 complex inactivates SIRT1 during mitosis and E2 acetylation on K111 by p300 increases, promoting interaction with Top1 that protects K112 from ubiquitination and therefore E2 proteasomal degradation. ImportanceHuman papillomaviruses are causative agents in around 5% of all human cancers. While there are prophylactic vaccines that will significantly alleviate HPV disease burden on future generations, there are currently no anti-viral strategies available for the treatment of HPV cancers. To generate such reagents, we must understand more about the HPV life cycle, and in particular about viral-host interactions. Here we describe a novel mitotic complex generated by the HPV16 E2 protein interacting with the host protein TopBP1 that controls the function of the deacetylase SIRT1. The E2-TopBP1 interaction disrupts SIRT1 function during mitosis in order to enhance acetylation and stability of viral and host proteins. This novel complex is essential for the HPV16 life cycle and represents a novel anti-viral therapeutic target.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Journal of Virology
499 papers in training set
Top 0.5%
18.2%
2
Journal of Biological Chemistry
690 papers in training set
Top 0.6%
11.7%
3
Cell Cycle
17 papers in training set
Top 0.1%
8.8%
4
PLOS ONE
5266 papers in training set
Top 22%
7.8%
5
PLOS Pathogens
820 papers in training set
Top 2%
6.6%
50% of probability mass above
6
Nucleic Acids Research
1281 papers in training set
Top 4%
5.4%
7
mBio
833 papers in training set
Top 3%
5.4%
8
Human Molecular Genetics
141 papers in training set
Top 0.7%
3.2%
9
Journal of Cell Science
393 papers in training set
Top 2%
2.7%
10
Molecular and Cellular Biology
47 papers in training set
Top 0.2%
2.7%
11
The FASEB Journal
194 papers in training set
Top 2%
2.4%
12
Scientific Reports
3612 papers in training set
Top 48%
2.1%
13
PLOS Genetics
862 papers in training set
Top 7%
1.7%
14
International Journal of Molecular Sciences
494 papers in training set
Top 9%
1.5%
15
Frontiers in Immunology
638 papers in training set
Top 9%
1.0%
16
iScience
1154 papers in training set
Top 36%
0.8%
17
Cells
249 papers in training set
Top 7%
0.8%
18
eLife
5828 papers in training set
Top 69%
0.6%
19
Virology
61 papers in training set
Top 1%
0.6%
20
mSphere
302 papers in training set
Top 8%
0.6%
21
DNA Repair
19 papers in training set
Top 0.2%
0.6%
22
Viruses
332 papers in training set
Top 5%
0.6%
23
EMBO Reports
263 papers in training set
Top 9%
0.6%
24
Microorganisms
106 papers in training set
Top 4%
0.6%
25
Life Science Alliance
285 papers in training set
Top 9%
0.6%